title: Fatty acids platelets and oxidative markers following intravenous n-3 fatty acids administration in cystic fibrosis: An open pilot observational study.
abstract: BACKGROUND
  An imbalance in the ratio of arachidonic acid and docosahexaenoic acid (DHA) was found in cystic fibrosis (CF) affected tissues and was suggested to promote inflammation. Several studies have shown that the long chain n-3 fatty acids reduced inflammatory activity while others have highlighted prooxidant activity of DHA at high concentrations. The aim of our study was to evaluate the effects of an intravenous fish-oil emulsion enriched with n-3 FA in patients with CF on plasma and platelet FA composition and peroxidation markers.
  
  
  METHODS
  13 patients with CF received one IV emulsion per week of 2 mL/kg fish-oil n-3 emulsion for 12 weeks.
  
  
  RESULTS
  There was a significant increase in 20:5 n-3 and 22:6 n-3 platelet FA composition, no variation in 20:4 n-6, a decrease in n-9. There was no variation in plasma FA composition. Specific urinary markers of lipid peroxidation derived from n-3 and n-6 showed a very high level before infusion compared with usual values in healthy subjects which was not affected by treatment. A significant weight loss and a decrease in reduced glutathione were observed in adult patients.
  
  
  CONCLUSIONS
  The intravenous administration of n-3 FA in CF patients induced a significant modification in platelet FA composition but no modification of oxidative markers. However, the weight loss and the decreased level in reduced glutathione observed in adult patients may suggest a potential deleterious activity for some patients. Further studies are necessary to determine the optimal dose and route for long chain FA administration required to reach a potential beneficial effect.
authors.affiliation: Department of Internal Medicine and Cystic Fibrosis Adult Center, University Claude Bernard Lyon 1, Centre Hospitalier Lyon-Sud, 69495 Pierre-Benite cedex, France. isabelle.durieu@chu-lyon.fr
authors.forename: Isabelle
authors.initials: I
authors.lastname: Durieu
authors.forename: Evelyne
authors.initials: E
authors.lastname: Vericel
authors.forename: Daniel
authors.initials: D
authors.lastname: Guichardant
authors.forename: Hubert
authors.initials: H
authors.lastname: Roth
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Steghens
authors.forename: Jocelyne
authors.initials: J
authors.lastname: Drai
authors.forename: Raphaele Nove
authors.initials: RN
authors.lastname: Josserand
authors.forename: Eric
authors.initials: E
authors.lastname: Fontaine
authors.forename: Michel
authors.initials: M
authors.lastname: Lagarde
authors.forename: Gabriel
authors.initials: G
authors.lastname: Bellon
mesh_terms: D000293:Adolescent; D000328:Adult; D015415:Biomarkers / Q000032:analysis; D001792:Blood Platelets / Q000737:chemistry*; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000378:metabolism*; D005227:Fatty Acids / Q000097:blood*; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage / Q000494:pharmacology*; D005979:Glutathione Peroxidase / Q000097:blood; D006801:Humans; D007275:Injections, Intravenous; D010084:Oxidation-Reduction; D010865:Pilot Projects
chemical_list: D015415:Biomarkers; D005227:Fatty Acids; D015525:Fatty Acids, Omega-3; D005979:Glutathione Peroxidase